Neostigmine and Dexamethasone in Adductor Canal Block

Overview

To compare between the efficacy of neostigmine and dexamethasone as an adjuvant to bupivacaine in adductor canal block after knee arthroscopy surgery.

Full Title of Study: “A Comparative Study Between Neostigmine and Dexamethasone as an Adjuvant to Bupivacaine in Adductor Canal Block After Knee Arthroscopy Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: July 27, 2022

Detailed Description

90 participants in this study will be randomized into three groups based on computer generated numbers using computerized generated random tables. The patients enrolled in the study will be transferred to the operation room and monitored all through the surgical procedure using pulse oximeter, non-invasive blood pressure and ECG. To perform spinal anesthesia ,the patient will be positioned in the sitting position then sterilization of the back using betadine solution 5% will be done then the iliac crest will be identified and the opposite intervertebral space(L4-L5) will be marked then 5 ml of lidocaine 2% will be infiltrated in the skin and subcutaneous tissue then a spinal needle (25G) will be introduced to the intrathecal space and after ensuring that clear cere¬brospinal fluid will be in free flow injection of 15-20mg of bupivacaine 0.5% and 25mcg of fentanyl will be administrated then the patient will be positioned in the supine position. If hypotension, (decrease in the mean arterial blood pressure of more than 20%from base line) occurs, 9mg intravenous ephedrine will be given with 200ml bolus crystalloids. If bradycardia (heart rate below 50beat / minute) occurs, 0.5mg intravenous atropine will be given. After the surgical procedure the patients will be randomly allocated using computerized generated random tables in to three equal groups and the random numbers will be concealed in closed opaque envelopes which will be kept by the senior anesthesia staff, the three groups are: – Group neostigmine: The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block. – Group dexamethasone: The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block. – Group control: The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group). With the patient in the supine position, the procedural needle (Braun Stimuplex Ultra Insuflated Echogenic Needle 22G) will be inserted in plane from the anteromedial side at the mid thigh level. It will be advanced through the sartorius muscle and fascia under ultrasound guidance, using a Siemens Acuson X300 ultrasound equipped with a linear transducer after sterilization of the skin with betadine solution 5%, and the adductor canal, with the superficial femoral artery and vein within, will be identified. Once the needle tip will be located in the adductor canal, the anaesthetic solution will be injected anterior to the artery and deep into the sartorius muscle (24) then patient will be transferred to the PACU then to the ward. Postoperative 1. Postoperative pain will be assessed by visual analog scale (VAS) 2. A fixed dose of intravenous paracetamol 1 gram will be given every 6 hours to all patients in the three groups starting from 1 hour after the ACB. 3. Postoperative pain assessment through VAS will be according to the scale as follow: – Pain level 0: no pain – Pain level1-3: mild pain – Pain level 4-6: moderate pain – Pain level 7-10: severe pain 4. Postoperative pain will be managed as follow: – Mild pain will be treated with ketolac 30mg IV. – Moderate pain will be treated with ketolac 30mg IV + morphine 0.07mg/kg IV. – Severe pain will be treated with ketolac 30mg IV & morphine 0.1mg/kg IV. Then patient will be reassessed and recorded as mentioned above and the specific treatment will be repeated after 8 hours from the initial dose according to VAS. 5. Opioids complications such as respiratory depression will be recorded and managed supportively by oxygen mask, controlled airway and if persistent or severe hypoventilation occurs positive pressure ventilation may be needed, nausea and vomiting will be treated with ondansterone (4mg IV).

Interventions

  • Drug: Dexamethasone
    • adductor canal block
  • Drug: neostigmine
    • adductor canal block
  • Other: NaCl solutions
    • adductor canal block

Arms, Groups and Cohorts

  • Placebo Comparator: Group C
    • The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
  • Active Comparator: Group D
    • The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
  • Active Comparator: Group N
    • The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.

Clinical Trial Outcome Measures

Primary Measures

  • first rescue analgesia time
    • Time Frame: 24 hours
    • Time (in hours) of first rescue analgesia (morphine) requirement for each group in the first 24 hours following the adductor canal block

Secondary Measures

  • morphine consumption
    • Time Frame: 24 hours
    • Total amount of morphine consumed in the first 24 hours following the AC
  • Visual analogue scale
    • Time Frame: up to 24 hours
    • VAS score at times 0-30 minutes, 1, 2, 4, 8, 12, 18 and 24 hours postoperatively. As visual analouge scale (VAS) is a scale from 0 to 10 where “0” means no pain and “10” means the most severe pain.
  • sensory block
    • Time Frame: up to 24 hours
    • Duration of sensory block at times 0-30 minutes, 1, 2, 4, 8, 12, 18 and 24 hours postoperatively
  • Presence of Nausea and vomiting
    • Time Frame: 24 hours
    • through a question answered by yes or no to identify the presence of nausea and vomiting

Participating in This Clinical Trial

Inclusion Criteria

  • patients undergoing knee arthroscopy surgery. – Age between 18 years and 65 years. – Both sexes – ASA I & ASA II Exclusion Criteria:

  • Patients' refusal – Allergy to any drug that will be used in the study – Psychological or mental disorders. – Disturbance of Conscious level. – Uncooperative patients – Coagulopathy – Contraindications to spinal anaesthesia (e.g.: severe mitral stenosis)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Heba Omar Ahmed, Associate professor of Anesthesia, pain management & surgical ICU – Cairo University
  • Overall Official(s)
    • Heba Omar, Principal Investigator, associate professor of anesthesia and surgical ICU, faculty of medicine, Cairo university

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.